Finding a T cell cancer antigen is like a needle in a haystack. As T.S Eliot wrote “The end is where we start from…”. Here we developed a foundational technology, MHC-I Snap based on de novo MHC - I fragmentation principle to rediscover more T cell epitopes. Our MHC-I Snap technology is central in building a library of tumor-specific antigens for Asian cancers. In an ongoing multi-collaborative effort in Singapore, we have thus established a T cell Monitoring and Vaccination platform (TMoVac) to translate potential T cell epitopes into personalized T cell vaccines for Asia-Pacific prevalent cancers. TMoVac is a diverse platform consisting of Epitope discovery, Epitope validation, Vaccine design and T-cell immune - monitoring. We will share our ongoing efforts to create values through innovative science and partnership.

Dr. Jackwee Lim is currently a Senior Scientist at the Singapore Immunology Network (SIgN), where he specializes in structural immunology. He has completed post-doctoral training at the University of Pennsylvania and the European Molecular Biology Laboratory before returning to Singapore. At SIgN, he oversees the mass cytometry platform, which supports immunology research across Asia. Dr. Lim is the pioneering inventor of the exchangeable and fragmentable major histocompatibility complex class I (MHC class I) molecules. He is dedicated to advancing next- generation MHC class I and II technologies aimed at rediscovering T cell antigens and their cognate receptors, with the goal to radically improve outcomes for cancer patients. In addition to his research, Dr. Lim serves on the editorial boards of three international journals and has co-founded a startup that commercializes technologies developed in his lab. His work is characterized by a commitment to innovation and collaboration in the field of immunology